Acute Myelogenous Leukemia (AML) Clinical Trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 532 clinical trials
Study of a New Intravenous Drug Called S65487 in Patients With Acute Myeloid Leukemia Non Hodgkin Lymphoma Multiple Myeloma or Chronic Lymphocytic Leukemia

))/ Recommended Phase 2 Doses (RP2D(s)) of S65487 as single agent administered intravenously (i.v.) in adult patients with refractory or relapsed Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma (NHL), Multiple

  • 17 views
  • 24 Feb, 2021
  • 17 locations
A Study of H3B-8800 in Participants With Myelodysplastic Syndromes Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia

-8800 in subset of participants with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). The study consists of two parts, a dose escalation part

azacitidine
decitabine
myelodysplastic syndromes
chronic myelomonocytic leukemia
leukemia
  • 0 views
  • 23 Mar, 2021
  • 27 locations
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Relapse Free Survival (RFS) in AML patients compared to Best Supportive Care (BSC) when given as maintenance therapy following allogeneic stem cell transplantation (SCT). This study will have 2 parts: Part …

azacitidine
blast cells
cell transplantation
venetoclax
bone marrow procedure
  • 88 views
  • 18 Jun, 2021
  • 196 locations
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

The purpose of the phase 1 portion (dose escalation) of the study will be to establish an optimally safe and biologically active recommended phase 2 dose (RP2D) and/or to determine maximum tolerated dose (MTD) for gilteritinib in sequential combination with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). The purpose of …

hematopoietic growth factors
blast cells
granulocyte colony stimulating factor
fludarabine
cytarabine
  • 0 views
  • 18 Jun, 2021
  • 17 locations
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS) Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (AML)

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants …

blast cells
azacitidine
pevonedistat
myelodysplastic syndromes
leukemia
  • 341 views
  • 17 Jun, 2021
  • 320 locations
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML) Secondary Objectives: Safety and tolerability assessments Assessment of infusion

fludarabine
cytarabine
cyclophosphamide
lymphoblastic lymphoma
salvage therapy
  • 14 views
  • 14 Jun, 2021
  • 71 locations
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory high-risk myelodysplastic syndrome.

leukemia
myelodysplastic syndromes
serum bilirubin level
myeloid leukemia
hydroxyurea
  • 0 views
  • 19 Jun, 2021
  • 25 locations
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is

fludarabine
blast cells
cytarabine
busulfan
hla-a
  • 0 views
  • 24 Jan, 2021
  • 1 location
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations

The AML18 Trial will evaluate several relevant therapeutic questions in Acute Myeloid Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome. The trial is primarily

blast cells
cytarabine
azacitidine
cladribine
vosaroxin
  • 381 views
  • 23 Jan, 2021
  • 83 locations
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of …

azacitidine
cytarabine
myeloid leukemia
aml/mds
leukemia
  • 0 views
  • 05 Apr, 2021
  • 95 locations